Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 9820181, 11 pages
https://doi.org/10.1155/2017/9820181
Review Article

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex

1Centre for Child Development, Neuropediatrics Unit, Pediatric Hospital, Coimbra Hospital and University Centre, Coimbra, Portugal
2Laboratory of Pharmacology & Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
3Centre for Neuroscience and Cell Biology-Institute for Biomedical Imaging and Life Sciences (CNC.IBILI) Research Consortium, University of Coimbra, Coimbra, Portugal

Correspondence should be addressed to Filipe Palavra; moc.liamg@arvalapepilif

Received 2 December 2016; Revised 11 February 2017; Accepted 21 February 2017; Published 12 March 2017

Academic Editor: Giuseppe Filomeni

Copyright © 2017 Filipe Palavra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Curatolo, R. Bombardieri, and S. Jozwiak, “Tuberous sclerosis,” The Lancet, vol. 372, no. 9639, pp. 657–668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Krueger and D. N. Franz, “Current management of tuberous sclerosis complex,” Pediatric Drugs, vol. 10, no. 5, pp. 299–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Osborne, A. Fryer, and D. Webb, “Epidemiology of tuberous sclerosis,” Annals of the New York Academy of Sciences, vol. 615, pp. 125–127, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. L. A. Devlin, C. H. Sheperd, H. Crawford, and P. J. Morrison, “Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland,” Developmental Medicine and Child Neurology, vol. 48, no. 6, pp. 495–499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-H. Hong, T. N. Darling, and C.-H. Lee, “Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study,” Neuroepidemiology, vol. 33, no. 4, pp. 335–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Northrup and D. A. Krueger, “Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference,” Pediatric Neurology, vol. 49, no. 4, pp. 243–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. P. B. Crino, K. L. Nathanson, and E. P. Henske, “The tuberous sclerosis complex,” The New England journal of medicine, vol. 355, no. 13, pp. 1345–1356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Laplante and D. M. Sabatini, “mTOR signaling in growth control and disease,” Cell, vol. 149, no. 2, pp. 274–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. United States of America Food and Drug Administration, Afinitor® (everolimus): summary of product characteristics, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s6lbl.pdf.
  10. European Medicines Agency, “Votubia® (everolimus): summary of product characteristics,” http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002311/WC500112238.pdf.
  11. R. Zoncu, A. Efeyan, and D. M. Sabatini, “MTOR: from growth signal integration to cancer, diabetes and ageing,” Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Palavra, A. F. Ambrósio, and F. Reis, “mTOR and neuroinflammation,” in Molecules to Medicine with mTOR: Translating Critical Pathways into Novel Therapeutic Strategies, K. Maiese, Ed., pp. 317–329, Elsevier Science & Technology Books and Academic Press, Cambridge, Mass, USA, 1st edition, 2016. View at Google Scholar
  13. R. Fernandes and F. Reis, “mTOR in diabetic nephropathy and retinopathy,” in Molecules to Medicine with mTOR: Translating Critical Pathways into Novel Therapeutic Strategies, K. Maiese, Ed., pp. 379–393, Elsevier Science & Technology Books and Academic Press, 1st edition, 2016. View at Google Scholar
  14. R. Loewith, E. Jacinto, S. Wullschleger et al., “Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control,” Molecular Cell, vol. 10, no. 3, pp. 457–468, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Wang and C. G. Proud, “MTORC1 signaling: what we still don’t know,” Journal of Molecular Cell Biology, vol. 3, no. 4, pp. 206–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Wong, “Mammalian target of rapamycin (mTOR) pathways in neurological diseases,” Biomedical Journal, vol. 36, no. 2, pp. 40–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Takei and H. Nawa, “mTOR signaling and its roles in normal and abnormal brain development,” Frontiers in Molecular Neuroscience, vol. 7, no. 1, article no. 28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Zhou and S. Huang, “The complexes of mammalian target of rapamycin,” Current Protein and Peptide Science, vol. 11, no. 6, pp. 409–424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Inoki, T. Zhu, and K.-L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Brugarolas, K. Lei, R. L. Hurley et al., “Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex,” Genes and Development, vol. 18, no. 23, pp. 2893–2904, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Schneider, R. H. Younis, and J. S. Gutkind, “Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma,” Neoplasia, vol. 10, no. 11, pp. 1295–1302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. E. Levy and C.-K. Lee, “What does Stat3 do?” Journal of Clinical Investigation, vol. 109, no. 9, pp. 1143–1148, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes and Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. D. D. Sarbassov, S. M. Ali, and D. M. Sabatini, “Growing roles for the mTOR pathway,” Current Opinion in Cell Biology, vol. 17, no. 6, pp. 596–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Yu, A. Parkhitko, and E. P. Henske, “Autophagy: an ‘Achilles’ heel of tumorigenesis in TSC and LAM,” Autophagy, vol. 7, no. 11, pp. 1400–1401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Yu, A. A. Parkhitko, and E. P. Henske, “Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy,” Proceedings of the American Thoracic Society, vol. 7, no. 1, pp. 48–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Parkhitko, F. Myachina, T. A. Morrison et al., “Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 30, pp. 12455–12460, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Alayev, Y. Sun, R. B. Snyder, S. M. Berger, J. J. Yu, and M. K. Holz, “Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells,” Cell Cycle, vol. 13, no. 3, pp. 371–382, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Alayev, R. S. Salamon, Y. Sun et al., “Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors,” American Journal of Respiratory Cell and Molecular Biology, vol. 53, no. 5, pp. 637–646, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Mota, “Sirolimus: a new option in transplantation,” Expert Opinion on Pharmacotherapy, vol. 6, no. 3, pp. 479–487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Baldo, S. Cecco, E. Giacomin, R. Lazzarini, B. Ros, and S. Marastoni, “mTOR pathway and mTOR inhibitors as agents for cancer therapy,” Current Cancer Drug Targets, vol. 8, no. 8, pp. 647–665, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Yuan, A. Kay, W. J. Berg, and D. Lebwohl, “Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy,” Journal of Hematology and Oncology, vol. 2, article 45, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Hietman, N. R. Movva, and M. N. Hall, “Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast,” Science, vol. 253, no. 5022, pp. 905–909, 1991. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Yang, D. G. Rudge, J. D. Koos, B. Vaidialingam, H. J. Yang, and N. P. Pavletich, “mTOR kinase structure, mechanism and regulation,” Nature, vol. 497, no. 7448, pp. 217–223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. MacKeigan and D. A. Krueger, “Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex,” Neuro-Oncology, vol. 17, no. 12, pp. 1550–1559, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. K. Patel and J. A. Kobashigawa, “Everolimus: an immunosuppressive agent in transplantation,” Expert Opinion on Pharmacotherapy, vol. 7, no. 10, pp. 1347–1355, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. U. Saran, M. Foti, and J.-F. Dufour, “Cellular and molecular effects of the mTOR inhibitor everolimus,” Clinical Science, vol. 129, no. 10, pp. 895–914, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Zanardi, E. Verzoni, P. Grassi et al., “Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma,” Therapeutic Advances in Urology, vol. 7, no. 3, pp. 152–161, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Spreafico and H. J. Mackay, “Current Phase II clinical data for ridaforolimus in cancer,” Expert Opinion on Investigational Drugs, vol. 22, no. 11, pp. 1485–1493, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Curatolo and R. Moavero, “mTOR inhibitors in tuberous sclerosis complex,” Current Neuropharmacology, vol. 10, no. 4, pp. 404–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Curatolo, M. Bjørnvold, P. E. Dill et al., “The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions,” Drugs, vol. 76, no. 5, pp. 551–565, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. J. P. Boni, B. Hug, C. Leister, and D. Sonnichsen, “Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations,” Seminars in Oncology, vol. 36, no. 3, pp. S18–S25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. M. Mita, J. Gong, and S. P. Chawla, “Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas,” Expert Review of Clinical Pharmacology, vol. 6, no. 5, pp. 465–482, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. D. N. Franz, J. Leonard, C. Tudor et al., “Rapamycin causes regression of astrocytomas in tuberous sclerosis complex,” Annals of Neurology, vol. 59, no. 3, pp. 490–498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J. J. Bissler, F. X. McCormack, L. R. Young et al., “Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis,” The New England Journal of Medicine, vol. 358, no. 2, pp. 140–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. D. M. Davies, S. R. Johnson, A. E. Tattersfield et al., “Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis,” The New England Journal of Medicine, vol. 358, no. 2, pp. 200–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. D. M. Davies, P. J. De Vries, S. R. Johnson et al., “Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial,” Clinical Cancer Research, vol. 17, no. 12, pp. 4071–4081, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Taillé, M.-P. Debray, and B. Crestani, “Sirolimus treatment for pulmonary lymphangioleiomyomatosis,” Annals of Internal Medicine, vol. 146, no. 9, pp. 687–688, 2007. View at Google Scholar · View at Scopus
  49. T. Ohara, T. Oto, K. Miyoshi et al., “Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis,” Annals of Thoracic Surgery, vol. 86, no. 6, pp. e7–e8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Sugimoto, A. Nakao, M. Yamane et al., “Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation,” Journal of Heart and Lung Transplantation, vol. 27, no. 8, pp. 921–924, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. A. M. Taveira-Dasilva, O. Hathaway, M. Stylianou, and J. Moss, “Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus,” Annals of Internal Medicine, vol. 154, no. 12, pp. 797–805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. F. X. McCormack, Y. Inoue, J. Moss et al., “Efficacy and safety of sirolimus in lymphangioleiomyomatosis,” New England Journal of Medicine, vol. 364, no. 17, pp. 1595–1606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Tarasewicz, A. Debska-Ślizień, J. Konopa, Z. Zdrojewski, and B. Rutkowski, “Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex,” Transplantation Proceedings, vol. 41, no. 9, pp. 3677–3682, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. G. Pressey, J. M. Wright, J. I. Geller, D. B. Joseph, C. S. Pressey, and D. R. Kelly, “Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex,” Pediatric Blood and Cancer, vol. 54, no. 7, pp. 1035–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. K. Koenig, A. A. Hebert, J. Roberson et al., “Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin,” Drugs in R&D, vol. 12, no. 3, pp. 121–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. D. A. Krueger, M. M. Care, K. Holland et al., “Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis,” New England Journal of Medicine, vol. 363, no. 19, pp. 1801–1811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. D. N. Franz, E. Belousova, S. Sparagana et al., “Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial,” The Lancet, vol. 381, no. 9861, pp. 125–132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. D. N. Franz, E. Belousova, S. Sparagana et al., “Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study,” The Lancet Oncology, vol. 15, no. 13, pp. 1513–1520, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Kotulska, D. Chmielewski, J. Borkowska et al., “Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex,” European Journal of Paediatric Neurology, vol. 17, no. 5, pp. 479–485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Cardamone, D. Flanagan, D. Mowat, S. E. Kennedy, M. Chopra, and J. A. Lawson, “Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex,” Journal of Pediatrics, vol. 164, no. 5, pp. 1195–1200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. D. A. Krueger, A. A. Wilfong, K. Holland-Bouley et al., “Everolimus treatment of refractory epilepsy in tuberous sclerosis complex,” Annals of Neurology, vol. 74, no. 5, pp. 679–687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Curatolo, “Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy,” Pediatric Neurology, vol. 52, no. 3, pp. 281–289, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. J. J. Bissler, J. C. Kingswood, E. Radzikowska et al., “Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 381, no. 9869, pp. 817–824, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. J. J. Bissler, J. C. Kingswood, E. Radzikowska et al., “Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial,” Nephrology Dialysis Transplantation, vol. 31, no. 1, pp. 111–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. S. A. Soefje, A. Karnad, and A. J. Brenner, “Common toxicities of mammalian target of rapamycin inhibitors,” Targeted Oncology, vol. 6, no. 2, pp. 125–129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Kaplan, Y. Qazi, and J. R. Wellen, “Strategies for the management of adverse events associated with mTOR inhibitors,” Transplantation Reviews, vol. 28, no. 3, pp. 126–133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. R. R. Martel, J. Klicius, and S. Galet, “Inhibition of the immune response by rapamycin, a new antifungal antibiotic,” Canadian Journal of Physiology and Pharmacology, vol. 55, no. 1, pp. 48–51, 1977. View at Publisher · View at Google Scholar · View at Scopus
  68. D. A. Krueger, M. M. Care, K. Agricola, C. Tudor, M. Mays, and D. N. Franz, “Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma,” Neurology, vol. 80, no. 6, pp. 574–580, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. T. H. Sasongko, N. F. Ismail, and Z. Zabidi-Hussin, “Rapamycin and rapalogs for tuberous sclerosis complex,” The Cochrane Database of Systematic Reviews, no. 7, Article ID CD011272, 2016. View at Google Scholar
  70. P. B. Crino, “The mTOR signalling cascade: paving new roads to cure neurological disease,” Nature Reviews Neurology, vol. 12, no. 7, pp. 379–392, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. A. di Nardo et al., Cell biology of TSC-deficiency in neurons. Personal communication, presented at the International TSC Research Conference, Lisbon, 3-5 November 2016.
  72. M. E. Feldman and K. M. Shokat, “New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of tor kinase domain inhibitors (TORKinibs),” Current Topics in Microbiology and Immunology, vol. 347, no. 1, pp. 241–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. S.-Y. Sun, “mTOR kinase inhibitors as potential cancer therapeutic drugs,” Cancer Letters, vol. 340, no. 1, pp. 1–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. J. C. Kingswood, P. Bruzzi, P. Curatolo et al., “TOSCA—first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex,” Orphanet Journal of Rare Diseases, vol. 9, p. 182, 2014. View at Publisher · View at Google Scholar · View at Scopus